Announces Pricing of Public Offering of Common Stock
Summary
--(BUSINESS WIRE)--Aug. 9, 2022-- (NASDAQ: KRTX) (Karuna), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced the pricing of an upsized underwritten public offering of 3,488,373 shares of its common stock at a public offering price of per share. Stifel, and are acting as lead managers, and , a , and Wedbush PacGrow are acting as co-managers for the offering.The shares are being offered by Karuna pursuant to an effective shelf registration statement that was previously filed with the (SEC). A preliminary prospectus supplement relating to and describing the terms of the offering has been filed with the and is available on the SECs website at www.sec.gov.When available, copies of the final prospectus supplement relating to these securities may also be obtained from the offices of , Attention: Prospectus Department, , 10282, or by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; , Attention: Broadridge Financial Solutions, , 11717, or by telephone at (866) 803-9204, or by email at prospectus-eq_fi@jpmchase.com; or , Attention: , , 2nd Floor, 10022, or by telephone at (877) 821-7388, or by e-mail at Prospectus_Department@Jefferies.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions.This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including among other things, the timing and completion of the public offering, and other statements identified by words such as could, expects, intends, may, plans, potential, should, will, would, or similar expressions and the negatives of those terms. Forward-looking statements are not promises or guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond our control. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, market risks and the satisfaction of customary closing conditions for an offering of securities.